Cargando…
Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds
Adenoviral gene therapy and oncolysis would critically benefit from targeted cell entry by genetically modified capsids. This requires both the ablation of native adenovirus tropism and the identification of ligands that remain functional in virus context. Here, we establish cell type-specific entry...
Autores principales: | Behr, Michael, Kaufmann, Johanna K., Ketzer, Patrick, Engelhardt, Sarah, Mück-Häusl, Martin, Okun, Pamela M., Petersen, Gabriele, Neipel, Frank, Hassel, Jessica C., Ehrhardt, Anja, Enk, Alexander H., Nettelbeck, Dirk M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997477/ https://www.ncbi.nlm.nih.gov/pubmed/24760010 http://dx.doi.org/10.1371/journal.pone.0095723 |
Ejemplares similares
-
EphA5 and EphA6: regulation of neuronal and spine morphology
por: Das, Gitanjali, et al.
Publicado: (2016) -
Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020) -
Ad 2.0: a novel recombineering platform for high-throughput generation of tailored adenoviruses
por: Mück-Häusl, Martin, et al.
Publicado: (2015) -
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
por: Hatano, Manabu, et al.
Publicado: (2004) -
Targeting EphA2 in cancer
por: Xiao, Ta, et al.
Publicado: (2020)